EARNINGS & TRADING: MP Evans restarts buybacks with new programme

Tue, 26th May 2026 18:15

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Blencowe Resources PLC - developing the Orom-Cross graphite project in Uganda - Pretax loss widens to GBP1.0 million for the six months ended March 31 from GBP184,568 a year prior. Exploration costs rise to GBP107,005 from nothing, and administrative fees and other expenses increase to GBP910,929 from GBP161,205. Says the company's next hurdle is to close project financing funding of around USD45 million to commence P1 production next year. Notes a variety of funding strategies are under consideration and with several interested parties considering investment. "The market has responded favorably and the Company's share price and market capitalisation reflect the progress made in 2025. The Company has received the support of existing and new shareholders during the period and will continue to work on adding further new institutional investors," says Blencowe.

----------

MP Evans Group PLC - Tunbridge Wells, England-based palm oil producer - Restarts share buybacks with new programme worth up to GBP2 million and running until the company's annual general meeting on June 12. Notes it will consider expanding the programme beyond the AGM, subject to shareholder approval. Says it is well positioned, "supported by strong operational cash generation and a robust balance sheet". Notes this presents an opportunity to buy back its shares at advantageous levels. Adds that any shares purchased will be cancelled.

----------

Poolbeg Pharma PLC - London-based clinical stage biopharmaceutical firm focused on cancer immunotherapy - Reports a positive outcome of a pre-Investigational New Drug meeting with the US Food & Drug Administration for its lead asset, POLB 001, which is a potential preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome. Notes the FDA feedback is "broadly aligned" with key aspects of the company's envisioned development pathway for the asset, and believes there is an "attractive route to market" for POLB 001. Adds that the feedback reaffirms the appeal of the programme to potential partners. Says the overall clinical development strategy was discussed, with alignment regarding the proposed primary endpoint for a future phase three clinical trial. "We received constructive feedback from the FDA and achieved broad alignment on several important aspects of the development pathway for POLB 001," says Bruno Speder, vice president of regulatory affairs.

----------

Cardiogeni PLC - Stratford-Upon-Avon, England-based developer of cell therapy medicines to treat heart failure - Notes that following the completion of the share exchange agreement announced late last month, it has fully repaid the convertible loan notes referenced in the admission documents. Says the CLN repayment totalled GBP810,000 and represents a full and final payment to the convertible loan note holders.

----------

Kazera Global PLC - mining investment firm focused on early-stage assets - Wholly-owned subsidiary Whale Head Minerals (Pty) Ltd enters into binding production sharing agreement with South African mineral processing company Rare Earth Minerals International (Pty) Ltd. Says this is regarding the Walviskop Heavy Mineral Sands project in the Northern Cape, South Africa. Explains that the agreement takes effect from June 1 and possesses an initial term of 12 months. The company expects it to "materially enhance operational capability, accelerate production growth and significantly reduce the working capital burden associated with scaling operations at Walviskop." Commenting on the agreement, Interim Chief Executive Richard Jennings says: "This agreement represents a potentially pivotal moment for Kazera and, in my view, materially changes the trajectory of our Walviskop project...Beyond materially reducing the working capital burden associated with scaling production, this partnership provides a clear pathway toward increasing both production volumes and concentrate quality over the coming weeks and months. We believe this has the potential to materially transform the economics of Walviskop and strengthen its position within the heavy mineral sands market."

----------

EnergyPathways PLC - West Sussex, England-based energy infrastructure project company - Appoints Martyn Hargrave as its chief scientific adviser to the chief executive and board. Notes the appointment enhances the firm's technical, strategic and policy capability, "as it advances its Mesh energy storage project and its broader integrated energy, hydrogen and industrial materials ambitions." Notes the Mesh project is expected to be Britain's largest integrated energy storage project. Notes Hargrave's over 40 years of experience across subsurface technology, energy systems and industrial innovation. Adds that he is the founder and CEO of subsurface software company Ikon Science which was acquired by Constellation Software in 2025. "Martyn brings an exceptional combination of scientific depth, entrepreneurial experience, and strategic insight. His background will be highly valuable as we advance MESH and broaden the strategic relevance of the project, including its potential role in long duration energy storage, hydrogen and graphite-linked industrial opportunities," says Chief Executive Ben Clube.

----------

Kendrick Resources PLC - mineral exploration and development company with projects in Namibia and Sweden - Reports fundraising of GBP1.8 million via the issue of 25.2 million shares at 7 pence per share, with directors, a US managed fund, a US family office as well as existing shareholders participating. Says proceeds are earmarked for advancing the Bonya Rare Earth project in Namibia, "where a drilling program is underway targeting a maiden JORC resource by the end of Q3 2026". Also intends to use the proceeds for advancing the strategic development and operational delivery plan announced earlier this month, as well as for working capital requirements.

----------

CRISM Therapeutics Corp - British Virgin Islands-based pharmaceutical firm - Raises GBP2.5 million through an oversubscribed placing of 25.0 million shares at 10 pence per share to both new and existing investors. Also announces a separate retail offer to raise up to GBP100,000 at the same issue price. Says proceeds will provide the company with finance to help secure "significant" grant funding, help progress phase two open-label clinical trial of irinotecan-ChemoSeed for the treatment of glioblastoma, offer additional working capital and support the development of docetaxel-ChemoSeed for prostate cancer. "This fundraise represents a pivotal moment for CRISM Therapeutics, providing the necessary capital to take us beyond the critical milestone of dosing our first patient in our Phase 2 open label clinical trial of irinotecan-ChemoSeed for glioblastoma, a disease where patients need better options," says CEO

Andrew Webb.

----------

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com